fluorouracil has been researched along with Brain Stem Neoplasms, Primary in 1 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas." | 9.17 | Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. ( Banerjee, A; Blaney, SM; Boyett, JM; Brownstein, C; Chintagumpala, M; Gururangan, S; Hussain, S; Kilburn, LB; Kocak, M; Kun, L; Meneses-Lorente, G; Paulino, AC; Schaedeli Stark, F; Thompson, PA, 2013) |
| "We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas." | 5.17 | Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. ( Banerjee, A; Blaney, SM; Boyett, JM; Brownstein, C; Chintagumpala, M; Gururangan, S; Hussain, S; Kilburn, LB; Kocak, M; Kun, L; Meneses-Lorente, G; Paulino, AC; Schaedeli Stark, F; Thompson, PA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kilburn, LB | 1 |
| Kocak, M | 1 |
| Schaedeli Stark, F | 1 |
| Meneses-Lorente, G | 1 |
| Brownstein, C | 1 |
| Hussain, S | 1 |
| Chintagumpala, M | 1 |
| Thompson, PA | 1 |
| Gururangan, S | 1 |
| Banerjee, A | 1 |
| Paulino, AC | 1 |
| Kun, L | 1 |
| Boyett, JM | 1 |
| Blaney, SM | 1 |
1 trial available for fluorouracil and Brain Stem Neoplasms, Primary
| Article | Year |
|---|---|
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Brain Stem Neoplasms; Capecitabine; Chemoradioth | 2013 |